The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Unity Software Inc. (U - Free Report) .
Unity Software currently has an average brokerage recommendation (ABR) of 1.79, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 24 brokerage firms. An ABR of 1.79 approximates between Strong Buy and Buy.
Of the 24 recommendations that derive the current ABR, 14 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 58.3% and 4.2% of all recommendations.
Brokerage Recommendation Trends for U
Check price target & stock forecast for Unity Software here>>>
The ABR suggests buying Unity Software, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is U Worth Investing In?Looking at the earnings estimate revisions for Unity Software, the Zacks Consensus Estimate for the current year has increased 144.4% over the past month to $1.03.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Unity Software. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Unity Software may serve as a useful guide for investors.
Unity Software delivered excellent Q1 results, and Q2 guidance was similarly upbeat. U's strategic focus on indie and small studio developers, combined with a leaner cost structure, positions it to benefit as the industry shifts away from blockbuster triple-A titles. Vector AI-driven advertising is a key growth driver, with Vector revenues up 80% YoY and the Grow division guiding for ~50% growth in Q2.
AstraZeneca PLC (LON: AZN - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts
AstraZeneca PLC (LON: AZN - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of £134.71 and traded as high as £140.80. AstraZeneca shares last traded at £140.76, with a volume of 214,151,109 shares traded. Analyst Ratings Changes A number of analysts have
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard on a subdued Friday session, after its experimental COPD treatment tozorakimab succeeded in two late-stage clinical trials.
The results mark the first positive phase III readout from a programme of more than 20 major data releases AstraZeneca expects to deliver in 2026, each adding weight to the company's ambition to reach $80 billion in annual revenue by 2030.
Tozorakimab met its primary endpoint in both the OBERON and TITANIA trials, reducing the rate of moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD), the progressive lung condition that is the third leading cause of death worldwide, affecting nearly 400 million people.
The drug works by blocking interleukin-33 (IL-33), a protein the body releases in response to damage or irritation in the airways.
When IL-33 is activated, it triggers inflammation and contributes to the build-up of excess mucus that makes breathing progressively harder for COPD patients, setting off a damaging cycle of worsening that can lead to hospitalisation or death.
By intercepting IL-33 at source and neutralising both its active and oxidised forms, tozorakimab aims to break that cycle simultaneously at two points: cooling the inflammatory response and clearing the mucus dysfunction that standard inhaled therapies cannot adequately address.
The trials enrolled patients who were still experiencing exacerbations despite being on standard inhaled treatments, a population with significant unmet medical need.
Tozorakimab, administered as a 300mg injection every four weeks on top of existing therapy, reduced exacerbation rates in both former smokers, the primary study population, and in the broader group, including current smokers and patients across all levels of a blood marker called eosinophils, a type of white blood cell often used to categorise COPD patients for treatment.
The drug was described as generally well-tolerated with a favourable safety profile.
Frank Sciurba, professor of pulmonary and critical care medicine at the University of Pittsburgh and chief investigator of the trial programme, said the results suggested meaningful clinical benefit across a broad COPD population, regardless of smoking status or eosinophil levels.
Sharon Barr, AstraZeneca's executive vice president of biopharmaceuticals research and development, described the outcome as a major scientific advancement, noting that tozorakimab is the first IL-33-targeting biologic to demonstrate statistically significant reductions in COPD exacerbations across two replicate phase III trials.
Two further last-stage clinical evaluations of tozorakimab in COPD, PROSPERO and MIRANDA, are ongoing, alongside separate studies in severe viral lower respiratory tract disease and asthma.
Graphene Manufacturing Group Ltd (TSX-V:GMG, OTCQX:GMGMF) announced that it has been certified as a Verified Graphene Producer by the Advanced Carbons Council.
The certification is part of the council’s Verified Graphene Producer program, which involves third-party validation of both the graphene material and its production process.
The process includes on-site inspections of manufacturing facilities and testing through independent laboratories to confirm the material’s origin and characteristics. The program follows established international standards for graphene classification and measurement.
In addition to the certification, the company reported that it has passed a recent ISO 9001:2015 quality audit covering its manufacturing, distribution, and technical support operations. The ISO 9001 standard is widely used to assess quality management systems across industries.
Craig Nicol, GMG’s CEO, said the verification places the company among a limited number of globally recognized graphene producers.
“Verification by the Advanced Carbon Council as one of five currently verified global graphene producers is another proof of the high quality of our graphene and why our graphene products function at such a world leading standard,” Nicol said.
He added that the successful quality system audit demonstrates the company’s ability to translate its materials into commercially viable products.
Jack Perkowski, chairman and non-executive director, described the third-party validation as an important milestone for the company’s operations in advanced materials.
“Congratulations to the team on getting this third-party verification on the graphene and quality management system — a real table stake when it comes to producing carbon nano material products,” Perkowski said.
The certification was also welcomed by the council. Terrance Barkan, executive director of the Advanced Carbons Council, said the program provides independent assurance to stakeholders evaluating graphene suppliers.
“We are proud to count Graphene Manufacturing Group as the newest member of a select group of graphene companies to have passed a rigorous in-person inspection of their facilities and a thorough examination of their graphene material,” Barkan said.
He noted that third-party validation can be a valuable tool for customers and investors when assessing producers.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation associated with aging.
The company highlighted that neuro inflammation is widely recognized as a contributing factor to cognitive decline in age-related neurological conditions.
The study found that nasal delivery of anti-CD3 therapy was able to reverse several key features of brain aging and improve cognitive performance in preclinical models.
Among the primary findings, the therapy appeared to reduce activation of microglia—immune cells in the brain that, when overactive, can drive chronic inflammation. This reduction in neuroinflammation is considered significant, as persistent inflammatory processes have been strongly linked to age-related cognitive decline.
The study also reported increased neurogenesis in the hippocampus, a region of the brain essential for memory and learning. In addition, the treatment was associated with reduced cellular senescence, achieved through the downregulation of inflammatory markers and genes linked to aging.
Howard Weiner, chairman of the company’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, said the findings add to a growing body of evidence supporting the therapy’s mechanism.
“By targeting T cells to influence microglial behavior and promote brain repair mechanisms like neurogenesis, nasal anti-CD3 offers a differentiated, non-invasive approach with potential applications in age related cognitive impairment,” Weiner said.
Tiziana CEO Ivor Elrifi added that the that the results reinforce the proposed mechanism of intranasal foralumab, which involves stimulating regulatory T cells to reduce neuroinflammation.
Tiziana is currently evaluating intranasal foralumab in clinical trials for several neurological conditions, including non-active secondary progressive multiple sclerosis, multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer’s disease. The company is also expanding its preclinical research into additional applications related to aging.
Shares of Tiziana added 6.8% on Wednesday morning.
New Era Energy & Digital (NASDAQ:NUAI) announced that it has signed a non-binding letter of intent to form a joint venture aimed at developing and financing its Texas Critical Data Centers (TCDC) campus in West Texas.
The proposed partnership would bring together New Era, data center developer Stream Data Centers, and an unnamed institutional investor that would provide equity capital and help arrange project financing.
The collaboration is intended to support the construction of a large-scale data center campus designed for artificial intelligence and high-performance computing workloads.
Under the terms outlined in the letter of intent, New Era is expected to contribute control of the project site and local relationships, while Stream Data Centers would take on responsibilities related to development, leasing, and operations.
The institutional investor would lead financing efforts, which are expected to include a significant portion of debt funding.
New Era said that it plans to remain an active stakeholder in the project by co-investing equity alongside the institutional partner, rather than acting solely as a land provider.
The company said this structure could allow it to generate ongoing revenue through distributions tied to operating cash flow once initial phases of the project become operational.
The project is expected to be structured through a newly formed limited liability company. Governance provisions are anticipated to include protections and rights for New Era as a partner in the venture.
“The fact that Stream and a premier provider of infrastructure capital have chosen to partner with New Era validates both the strategic value of the TCDC campus and the strength of our development strategy and platform,” New Era CEO E. Will Gray II said in a statement.
“This LOI represents an important step in advancing TCDC toward delivery, and we remain focused on progressing toward a definitive agreement with Stream.”
The TCDC campus is planned for a 438-acre site near Odessa, Texas. It is designed as a multi-phase development, with projected capacity exceeding 1 gigawatt over time.
Shares of New Era were up 6.7% on Wednesday morning.
A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important growth drivers.
Liver cancer is one of the most difficult cancers to treat, and for patients whose tumours cannot be surgically removed, options have historically been limited.
That is what makes AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) latest clinical trial result significant.
The FTSE 100 drugmaker has shown that its immunotherapy Imfinzi, used in combination with three other treatments, can meaningfully delay disease progression in patients with unresectable hepatocellular carcinoma, the most common form of liver cancer, compared with the standard treatment alone.
Immunotherapies work by helping the body's own immune system recognise and attack cancer cells, rather than using chemotherapy to kill them directly.
The result, from a large-scale phase three trial called EMERALD-3, is the kind of rigorous clinical evidence that regulators require before approving a new treatment, meaning a formal application to bring the combination to market is now a realistic near-term prospect.
For AstraZeneca, the commercial implications are considerable.
Citi, which rates the company a buy, already forecasts Imfinzi will generate peak annual sales of $11 billion by 2030, a figure roughly 20% above what most City analysts currently expect, and this trial result helps support that case.
That puts the product in the super-blockbuster category, which is any drug with annual revenues above $10 billion.
Imfinzi is already approved in lung, bladder and bile duct cancers, and further trial readouts in bladder and oesophageal cancers are expected later this year.
Each successful indication adds another layer of revenue to what is rapidly becoming one of the most versatile drugs in AstraZeneca's portfolio, and a central pillar of its growth story.
UBS and Citi both maintain 'buy' ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich pipeline of clinical catalysts adding to the investment case.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports first-quarter 2026 results on 29 April, with UBS flagging several moving parts that investors will watch closely when the numbers land.
In a preview note, UBS highlights continued strong momentum expected from key cancer drugs Imfinzi, Tagrisso and Calquence, while cautioning that Farxiga, a treatment for type 2 diabetes and heart failure, is likely to show some impact from wholesaler destocking in the US ahead of its loss of exclusivity (LOE), the point at which generic competitors can enter the market.
UBS also flags that three AZ drugs faced volume-based procurement (VBP) in China during the quarter, a government-mandated pricing process under which the company chose not to offer price concessions and, as a result, was excluded from the programme, leaving Forxiga, Lynparza and roxadustat facing mandatory price cuts of 20%, 30% and 30%, respectively.
On the cost side, UBS anticipates higher selling and administrative expenses in the first quarter as AstraZeneca prepares for launches of camizestrant and baxdrostat, two drugs in late-stage development targeting breast cancer and cardiovascular disease, respectively.
UBS maintains its 'buy' rating and 12-month price target of 17,600p, implying upside of around 15% from the current price of 15,274p.
Citi is more bullish, raising its price target to £180 from £170 after updating its model for first-quarter developments, with the bank's earnings per share compound annual growth rate forecast for 2027 to 2030 rising to 15% from 13%.
Citi's upgrade reflects increased confidence in camizestrant following a rival drug's clinical failure, which Citi says expands the addressable market, and a significantly higher probability of success assigned to tozorakimab, a drug targeting lung disease, following positive headline trial data.
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare inflammatory kidney disease that can progress to kidney failure.
The results showed a statistically significant reduction in proteinuria, the presence of excess protein in urine that indicates kidney damage.
The interim results from the I CAN trial showed Ultomiris, known generically as ravulizumab, reduced proteinuria based on a 24-hour urine protein creatinine ratio (UPCR) at week 34, with reductions observed as early as week 10.
IgAN affects more than 560,000 people across the US, EU and Japan and occurs when abnormal proteins trigger immune complexes that deposit in the kidneys, activating the body's complement system, a branch of the immune response, and driving inflammation that progressively damages kidney tissue.
Ultomiris works by blocking the C5 protein in the terminal complement cascade, the final stage of this immune response, preventing the body from attacking its own kidney cells.
Jonathan Barratt, professor of renal medicine at the University of Leicester and a trial investigator, said many patients with IgAN continue to progress to kidney failure despite advances in care, and described the results as promising.
Marc Dunoyer, chief executive of Alexion, AstraZeneca Rare Disease, said the company intends to file the data with regulatory authorities in key markets and will seek accelerated approval.
The safety profile was consistent with Ultomiris's established record, with no new concerns identified.
The trial's second primary endpoint, measuring the rate of kidney filtration at week 106, will be assessed at the final analysis when the full study completes.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to delay its full-year 2025 results, according to Citi, which maintains a 'buy' rating on the stock.
Daiichi Sankyo, which partners with AstraZeneca on cancer treatments Enhertu and Datroway, has pushed its results publication back from 27 April to 11 May to allow additional time to estimate loss provisions linked to contract manufacturers, citing a review of supply plans across its oncology portfolio in light of rapidly changing business conditions.
Citi notes that Daiichi has previously flagged manufacturing difficulties, including minor Enhertu inventory write-downs of around $30 million in the second quarter of its 2025 financial year due to unqualified production lots, a problem since identified and resolved with no expected impact on supply.
The Japanese drugmaker also recorded around $110 million in compensation fees and inventory write-downs relating to contract manufacturers for Datroway and HER3-DXD, the latter developed in partnership with Merck, in the year to December 2025.
Citi's analysts believe the delay reflects Daiichi working through issues within its own manufacturing network rather than any fundamental problem with the Enhertu or Datroway franchises, which are forecast to contribute 6.5% and 11% of AstraZeneca's revenues in 2026 and 2030 respectively.
The bank sees little or no impact on sales of either drug and retains its positive stance on AstraZeneca's shares.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a key breast cancer setting.
The FTSE 100 drugmaker said the Oncologic Drugs Advisory Committee of the Food and Drug Administration (FDA) voted three to six against the benefit-risk profile of camizestrant in combination with a CDK4/6 inhibitor for first-line treatment of advanced hormone receptor-positive breast cancer.
AstraZeneca noted the FDA is not bound by the panel’s recommendation but will take it into account as it reviews the application.
The decision comes despite positive data from the Phase III SERENA-6 trial, which showed a 56% reduction in the risk of disease progression or death compared with standard care.
Median progression-free survival was 16.0 months for patients on the camizestrant combination versus 9.2 months for those on existing treatments.
Susan Galbraith, executive vice president of oncology R&D, said the company was “disappointed with the mixed outcome” but remained confident in the drug’s clinical benefit.
Regulatory reviews are ongoing in other regions including the EU and Japan.
Also on Friday, AstraZeneca saw more positive news elsewhere, with a separate FDA advisory panel voting seven to one in favour of its Truqap combination for a form of prostate cancer.
The treatment showed a 19% reduction in the risk of disease progression or death in late-stage trials, supporting its potential as a targeted option in an area of high unmet need.
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) told investors that it has lifted the scale of its South Prudhoe project in Alaska, upgrading total gross unrisked 2U prospective resources by around 35% to 768.9 million barrels of oil and natural gas liquids.
The company said the estimate equates to 640.7 million barrels net to 88E and confirms a multi-reservoir opportunity immediately south of the Prudhoe Bay Unit and Kuparuk River Unit on Alaska’s North Slope.
The update follows further geophysical analysis of Schrader Bluff 3D seismic velocity data. It includes a maiden Brookian prospective resource for the North-West Hub and an upgraded Ivishak estimate, particularly for the priority Augusta prospect.
The North-West Hub now carries 301.3 million barrels of gross unrisked 2U resources, while the South-East Hub contains 467.6 million barrels. Within the North-West Hub, the maiden Brookian estimate totals 181.5 million barrels gross 2U, including 61.2 million barrels at West Sak and 120.3 million barrels at Upper Schrader Bluff.
The Ivishak estimate for the North-West Hub increased around 44% to 69.9 million barrels gross 2U.
The planned Augusta-1 exploration well is now designed to test up to 133.7 million barrels gross unrisked 2U, or 111.4 million barrels net to 88E, across the Ivishak, Kuparuk and Brookian reservoir intervals.
88 Energy said Nordic Rig-3 has been secured for Augusta-1, with well planning, permitting and long-lead procurement advancing ahead of a planned drilling campaign during the CY2027 Alaskan winter season.
Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) has conditionally raised US$11.5 million to back a busy exploration programme, including drilling on the Chevron-operated Nabba-1 well in Namibia’s PEL 90.
The fundraise was priced at 22.5p per new common share on AIM and C$0.41 on the TSX-V, with the company set to issue 38.0 million new shares. The AIM price represents a 13.5% discount to Sintana’s 26p closing mid-market price on 14 May.
The raise comprises a US$10.8 million placing of 35.6 million shares and a US$0.7 million subscription for 2.37 million shares by directors and qualified investors from Canada and Australia. Chief executive Robert Bose and president Eytan Uliel each subscribed for 826,105 shares, investing US$250,000 apiece.
Bose said the oversubscribed fundraise, together with existing cash and proceeds from the Exxon settlement in Colombia, gives Sintana additional capital for Nabba-1 and the cash portion of acquisitions covering interests in PEL 37 in Namibia’s Walvis Basin and KON-16 in Angola’s Kwanza Basin.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class of blood pressure medication to reach the market in more than two decades.
The drug works by blocking production of aldosterone, a hormone that can raise blood pressure to dangerous levels and increase the risk of heart and kidney damage.
Roughly half of all patients in the US who take multiple blood pressure medications still cannot get their condition under control, making hypertension the leading modifiable risk factor for heart attack, stroke, kidney disease and dementia.
In clinical trials published in the New England Journal of Medicine, Baxfendy at its higher dose lowered the top blood pressure reading by nearly 16 points, with close to 10 points of that reduction attributable to the drug rather than placebo effect.
That level of improvement is considered clinically meaningful because evidence suggests every 10-point drop in the top reading is associated with a roughly 20% lower risk of serious cardiovascular events.
Ruud Dobber, executive vice president of AstraZeneca's biopharmaceuticals unit, said the drug "offers a much-needed, first-in-class innovation for people living with persistently uncontrolled hypertension who have not responded to or tolerated existing medicines".
Separately, US regulators have approved two new uses for AstraZeneca and Daiichi Sankyo's breast cancer drug Enhertu, allowing it to be used for the first time in earlier-stage disease where the goal is to cure rather than manage the cancer.
Enhertu has been approved for use both before and after surgery in patients with HER2-positive breast cancer, a particularly aggressive form of the disease driven by excess levels of a growth-promoting protein.
In the post-surgery trial, Enhertu cut the risk of the cancer returning or death by 53% compared with an existing treatment, with more than nine in ten patients alive and disease-free after three years.
The approvals trigger $155 million in milestone payments from AstraZeneca to its Japanese partner Daiichi Sankyo.
Enhertu is already approved in more than 95 countries for advanced breast cancer and now covers both early and late-stage disease in the US.
Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug Wainua, expected in the third quarter of 2026.
Wainua is a TTR-silencer, a drug that suppresses production of a protein called transthyretin (TTR) which can misfold and accumulate in the heart and nerves, causing a progressive condition known as ATTR-cardiomyopathy (ATTR-CM).
The CARDIO-TTRansform trial is a phase three study examining Wainua's efficacy specifically in ATTR-CM patients, a larger and more commercially significant population than the nerve disease indication for which the drug is already approved.
Citi believes there is a relatively high probability that the trial hits its primary endpoint, which would push its peak Wainua sales estimate for ATTR-CM to $6 billion, or $7 billion including the existing nerve disease approval.
This is well above the risk-adjusted consensus of around $3 billion and represents a 2% uplift to the bank's discounted cash flow valuation.
If a secondary endpoint showing benefit in patients already treated with stabiliser drugs is also met, Citi sees peak ATTR-CM sales reaching $8 billion and total Wainua sales of $9 billion, equivalent to a 4% DCF uplift.
Trial failure would represent a 3% DCF downside, but Citi notes that even in this scenario, its valuation remains more than 20% above the current share price, suggesting investors should treat any weakness as a buying opportunity.
Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, with the shares at 13,064p.
The bank's analyst judged the company's investor event at the American Society of Clinical Oncology (ASCO) annual conference in Chicago as broadly incremental, acknowledging AZ's formidable oncology track record while pointing to unresolved questions that temper enthusiasm.
The most closely watched data at ASCO was the phase III EMERALD-3 trial, which showed AstraZeneca's immunotherapy combination of Imfinzi (durvalumab) and Imjudo (tremelimumab), paired with lenvatinib and transarterial chemoembolisation (TACE), cut the risk of disease progression or death by 30% versus TACE alone in patients with unresectable liver cancer eligible for embolisation.
Despite the positive readout, Deutsche flagged uncertainty over whether EMERALD-3 will secure regulatory approval, a question it sees as unresolved alongside similar concerns about SERENA-6, AstraZeneca's breast cancer study of camizestrant, a next-generation oestrogen receptor degrader.
The bank also noted that ASCO 2026 marks the first conference since 2018 at which AstraZeneca has not featured in the prestigious plenary session, ending a remarkable eight-year run.
A second Deutsche Bank note, arising from a call with AstraZeneca's head of cardiovascular and renal research and development, flagged 2027 as a potentially significant year for pipeline catalysts, with phase III readouts expected for oral PCSK9 inhibitor laroprovstat, mineralocorticoid receptor antagonist balcinrenone and endothelin receptor antagonist zibotentan.
More immediately, the bank expressed caution over the early commercial trajectory of Baxfendy, a first-in-class hypertension treatment that recently received FDA approval, describing a third-party prescriber poll on the launch as mixed.
AstraZeneca's Wainua RNA-interference therapy for hereditary transthyretin amyloidosis is also expected to deliver a pivotal trial result in 2026, adding to a busy near-term catalyst schedule.
Lyft CEO David Risher told CNBC's "Squawk Box" on Friday that consumers are "rewards-maxxing." "That's the sort of thing that I think a lot of people are being really smart about, and saying how can I make my dollar go faster?
The rivalry between Uber Technologies and Lyft has traditionally revolved around the same core questions: Who could grow faster, subsidize rides longer and survive the brutal economics of ridesharing?
But as the most recent quarterly earnings from both mobility platforms reveal, the competitive frame has shifted. The market today is a mature one where profitability matters, and the next frontier is no longer simply moving people from point A to point B. It is about building the operating system for urban mobility, commerce and eventually autonomous transportation.
Both companies are growing. Both are profitable, although Uber posted quarterly results on Wednesday (May 6) that were better received by investors than Lyft’s Thursday (May 7) financials. Both firms, however, are leaning heavily into artificial intelligence (AI) and autonomous vehicles. But their visions of what comes next and how they plan to win could hardly be more different.
See also: Uber Makes Billion-Dollar Bet on Rivian Robotaxis
Uber Wants to Become Everyday Life Infrastructure Layer The contrast emerging from the companies’ latest earnings calls is striking. Uber increasingly resembles a sprawling mobility and logistics infrastructure platform, while Lyft is positioning itself as a more focused transportation company built around customer experience, premium services and strategic partnerships.
Uber CEO Dara Khosrowshahi described the company’s strategy as expanding “everyday utility” across travel, delivery, commerce and mobility. Uber reported 21% year-over-year gross bookings growth, accelerated mobility growth and a delivery business increasingly powered by grocery and retail.
Advertisement: Scroll to Continue
The company’s leadership also emphasized ecosystem metrics: 50 million Uber One members, 10 million drivers and couriers and rising cross-platform usage among consumers.
Uber no longer wants to own a single transportation moment; it wants to orchestrate the entire journey around it. That includes airport rides, hotel reservations, restaurant delivery, retail shopping and eventually autonomous fleets. The company says three-quarters of Uber rides already involve AI predicting where a customer wants to go before the destination is entered.
Uber also appears increasingly confident about autonomous vehicles. Not as a threat, but as a massive expansion opportunity. Khosrowshahi repeatedly framed autonomous vehicles (Avs) as a “$1 trillion TAM (total addressable market)” and described Uber’s role in this marketplace as the connective tissue between autonomous technology providers and real-world operations.
The launch of “Uber Autonomous Solutions” reflects a belief that the long-term value may not reside solely in the autonomous software itself, but in the surrounding infrastructure: fleet management, charging depots, financing, insurance, and rider demand.
Read also: Lyft Draws Big Spenders With Rewards and Partnerships
Lyft Counters With Rideshare Focus, Partnerships Lyft’s outlook was narrower but disciplined. CEO David Risher has spent the last several quarters emphasizing “customer obsession,” operational consistency and profitable growth.
Unlike Uber, Lyft is not trying to become a super app. It has no delivery business, no grocery ambitions, and no commerce marketplace layered atop transportation. Instead, Lyft is doubling down on mobility itself, and reported double-digit growth in riders, bookings, and EBITDA, while maintaining gains in U.S. rideshare market share.
One pillar of its strategy is partnerships. Lyft increasingly sees external ecosystems and not internal diversification as the path to customer acquisition and engagement. Partnerships with DoorDash, United Airlines, Hilton, Alaska Airlines and others are driving a growing percentage of ride demand. Partnership-tagged ride requests now account for roughly 27% of Lyft rides.
The company’s acquisitions of FREENOW and Gett also signal an international expansion model rooted in taxis, regulated markets and enterprise mobility rather than broad-based global rideshare competition. At the same time, executives repeatedly emphasized higher-value ride modes like Lyft Black, XXL vehicles, chauffeured services and airport-focused demand.
In many ways, Lyft is beginning to resemble a premium mobility network rather than a pure mass-market rideshare platform.
See also: Nvidia’s Automotive Business Emerges With 32% Growth in Q3
The Autonomous Future Could Reshape Competitive Balance The biggest strategic wildcard remains autonomous vehicles. Both companies insist AVs will expand the overall market rather than cannibalize existing rideshare demand. Both also claim early evidence that AV deployment is growing total rideshare usage rather than hurting their businesses.
Uber’s strategy is diversified and infrastructure heavy. It wants to integrate every major AV provider into its marketplace while monetizing the operational ecosystem surrounding them.
Lyft, meanwhile, appears more dependent on a smaller number of strategic AV relationships, particularly Waymo. But Lyft argues its operational intensity and utilization rates could make it an attractive long-term AV operator.
The clearest takeaway from this earnings season is that Uber and Lyft are no longer converging businesses. They are diverging.
Uber believes the future belongs to integrated ecosystems powered by AI, logistics, and cross-platform engagement. Lyft believes there is still substantial value in building a highly trusted, mobility-centric transportation brand.
The next decade will determine which vision proves more durable.
CoreWeave (CRWV) reported first quarter results on Thursday and missed Wall Street's guidance expectations. EMJ Capital founder and president Eric Jackson and Yahoo Finance Senior Business Reporter Ines Ferré chat with Yahoo Finance's Brian Sozzi about the earnings results and the outlook for Nvidia (NVDA) and artificial intelligence (AI) demand.
Lyft stock is showing downward pressure. What’s the outlook for LYFT shares? Lyft’s Mixed Q1 Results: Revenue Beats While EPS Lags Analyst EstimatesAfter Thursday's close, Lyft reported first-quarter EPS of 4 cents versus a 6 cents consensus estimate, while revenue came in at $1.65 billion versus $1.63 billion expected. Management also pointed to Gross Bookings of $4.9 billion (up 19%) and Active Riders of 28.3 million (up 17%), alongside CEO David Risher's comments on continued U.S. share gains and a Flexdrive AV operation in Nashville.
“Our customer-obsessed comeback continues,” said Risher, noting that Lyft met all financial goals and expanded U.S. market share. With double-digit growth in riders and bookings, CFO Erin Brewer highlighted a strong foundation and $1 billion in trailing twelve-month cash flow, setting the stage for accelerated growth in the second-quarter.
Critical Levels To Watch For LYFT StockAt $14.20, Lyft is trading 1.3% below its 20-day SMA ($14.25) but 2.4% above its 50-day SMA ($13.73), which fits a short-term stabilization attempt after the March swing low and the April rebound. The bigger-picture trend is still a headwind, with the stock trading 10.1% below its 100-day SMA ($15.64) and 19.2% below its 200-day SMA ($17.41), and the February death cross (50-day below 200-day) still in place.
Momentum is best read through RSI, which sits at 51.78—neutral and consistent with a stock that's trying to base rather than break out. In plain terms, RSI helps gauge whether buying or selling has become "stretched," and this reading suggests neither side has clear control right now.
Key Resistance: $14.00 — a nearby round-number/pivot area that can cap rebounds, especially with the 20-day SMA sitting just above current price Key Support: $13.00 — a nearby round-number level that lines up with where buyers have tended to step in as the stock holds above the 52-week low zone ($12.30) Is LYFT A Buy, Sell Or Hold? Wall Street Weighs InAnalyst Consensus & Recent Actions: The stock carries a Hold rating with an average price target of $18.17. Recent analyst moves include:
JP Morgan: Neutral (Raises Target to $18.00) (May 8) Truist Securities: Hold (Raises Target to $16.00) (May 8) RBC Capital: Outperform (Lowers Target to $18.00) (May 8) LYFT Stock Price Movement TodayLYFT Stock Price Activity: Lyft shares were flat at $14.09 at the time of publication on Friday, according to Benzinga Pro data.
Image: Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of StockMarketBeat
MarketAxess Holdings Inc. (NASDAQ:MKTX - Get Free Report) General Counsel Scott Pintoff sold 100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $116.03, for a total transaction of $11,603.00. Following the transaction, the general counsel owned 11,786 shares in the company, valued at approximately $1,367,529.58. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ:MKTX
Read Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of Stock
Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 327
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Lyft remains a compelling value play, trading at just 4.2x trailing and 3.6x forward free cash flow. Strategic partnerships with DoorDash, United Airlines, and others are driving record levels of partner-linked rides and supporting market share gains. Q1 results showed 14% revenue growth and 19% gross bookings growth, with adjusted EBITDA up 25% to $133 million.
Uber Technologies: Pushing for Broader RevenueUber Technologies (UBER 1.25%) develops applications that connect consumers with independent providers for mobility services, meal preparation, and freight logistics.
It announced a multi-year autonomous vehicle partnership with Nvidia, and it reported an approximately 15% EBIT margin for the quarter ended March 31, 2026.
Lyft: Steady Revenue From North American RidesharingLyft (LYFT 1.24%) operates a peer-to-peer marketplace providing on-demand transportation networks across the United States and Canada.
It completed an international acquisition of a black cab business in London, while reporting an approximately 1% net income margin for the quarter ended March 31, 2026.
Why Revenue Matters for Retail InvestorsRevenue shows the total money brought in before expenses are subtracted to help investors gauge raw business scale and growth.
Image source: The Motley Fool.
Quarterly Revenue for Uber Technologies and LyftQuarter (Period End)Uber Technologies RevenueLyft RevenueQ2 2024 (June 2024)$10.7 billion$1.4 billionQ3 2024 (Sept. 2024)$11.2 billion$1.5 billionQ4 2024 (Dec. 2024)$12.0 billion$1.6 billionQ1 2025 (March 2025)$11.5 billion$1.5 billionQ2 2025 (June 2025)$12.7 billion$1.6 billionQ3 2025 (Sept. 2025)$13.5 billion$1.7 billionQ4 2025 (Dec. 2025)$14.4 billion$1.6 billionQ1 2026 (March 2026)$13.2 billion$1.7 billionData source: Company filings. Data as of May 10, 2026.
Foolish TakeBoth Uber and Lyft began as ride-hailing services, but the comparison in their revenues reveals the former dominates its rival in capturing sales. Uber’s business has experienced substantial expansion compared to Lyft, as illustrated by its higher revenue, and its future sales may expand the gap further.
Uber has aggressively expanded internationally since 2011, while Lyft remained more focused on the North American market in its early years. Lyft’s 2026 purchase of Gett, a leading black cab business in London, demonstrates its desire to capture more international sales. However, the disparity in their top lines suggests Lyft has a long way to go to catch up to Uber.
In addition, while the two companies are aggressively pursuing self-driving cars, Uber appears to be in the driver’s seat here. It captured partnerships with a number of autonomous vehicle companies around the world, cementing its global presence in this emerging field.
Moreover, Uber’s deal with AI semiconductor leader Nvidia allows any car manufacturer using Nvidia’s self-driving tech to easily join Uber’s ride-hailing service. Uber expects to have 100,000 autonomous vehicles on the road by 2027. These moves mean Lyft may fall further behind its larger competitor, suggesting Uber is the better long-term stock investment.
Robert Izquierdo has positions in Nvidia and Uber Technologies. The Motley Fool has positions in and recommends Lyft, Nvidia, and Uber Technologies. The Motley Fool has a disclosure policy.
By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Lyft has rolled out its AI-based Earnings Assistant tool over the past year. Bloomberg/Getty Images Ride-hailing drivers can spend months or years learning the best ways to make money. Now, there's artificial intelligence for that.
Lyft has been rolling out over the past year Earnings Assistant, a AI tool that gives drivers tips on where and when to drive. It shows how the company hopes to use AI to help drivers earn more in an industry where they're paid per trip.
The tool has two features. One, called plan guidance, gives drivers advice on where to go to increase their chances of claiming rides, especially if they're planning to work on the app for a limited time. The option, available to drivers in the US, is meant to help new drivers find productive areas and times to work, a Lyft senior staff software engineer, Xiaoyi Duan, told Business Insider.
Another feature, called real-time guidance, pinpoints where Lyft customers need rides. Lyft is still testing this feature, which is live in most cities.
Lyft's Earnings Assistant feature shows drivers where they can go to claim rides. Lyft "Drivers want to earn more, and they see various signals in the app, but those signals are not tailored to drivers' personalized needs," Duan said.
Lyft is using AI to synthesize the information — such as where ride requests are coming in or when they tend to spike in certain areas — and make personalized recommendations. That could mean pointing a driver toward a stadium when a concert is about to end or suggesting they pick up their last ride of the day at an airport because it's the busiest time of day for arrivals.
Lyft and rival Uber each have millions of drivers globally, many of whom accept rides on both services, comparing the pay and features. Uber is beta-testing a similar AI feature to help drivers earn more on its app.
Ride-hailing drivers often learn how to maximize earnings on apps like Lyft and Uber as they gain experience. With millions of other people on the apps, though, claiming trips and making money can be competitive. And with no clear bosses or colleagues, figuring out how to make money on the apps is challenging.
Lyft created Earnings Assistant within the past two years, the company said. The company showed early versions of the tool to drivers at events in Dallas, Las Vegas, and Miami last fall. It also tested Earnings Assistant with drivers who offered rides near Santa Clara, California, for February's Super Bowl.
The testing showed that experienced drivers often know to look for patterns that could help them earn more money, so they want more tips about where to go in the moment, Yuko Yamazaki, vice president and head of driver at Lyft, told Business Insider.
Many new Lyft drivers, meanwhile, are initially overwhelmed by the options when they start using the app, Yamazaki told Business Insider. Yamazaki said the app's plan guidance focuses on these drivers and offers suggestions on where to work, such as, "Here is what the next two hours could look like."
"The real-time signals are becoming more of an interest for drivers as they become more mature on our platform," she said.
Duan said Lyft wants to expand the tool, which currently requires drivers to prompt it for suggestions. Future iterations could tell drivers they're near a busy event as they pass it, or indicate how the weather is affecting opportunities to make money, she said.
"We are not trying to build an AI product because we want to use AI," Duan said. "We're trying to find what are the actual driver needs. That's the fundamental thing."
Do you have a story to share about Lyft, Uber, or another ride-hailing service? Contact this reporter at [email protected] or via encrypted messaging app Signal at 808-854-4501. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Alex Bitter You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Alex Bitter is a senior retail reporter covering the gig economy, food, and retail. His work focuses major gig delivery and ride-hailing apps, including Uber, Lyft, DoorDash, Instacart, and Walmart's Spark. He is interested in everything from what it's like to work on the apps to the companies' business strategies.Some of his recent stories feature gig workers who have been deactivated on the apps, DoorDash hiring traditional employees to make deliveries, gig workers' use of bots, and gig work expanding into new professions, such as nursing.Alex has also written about Aldi's US expansion, Starbucks' turnaround efforts, and the fallout from Kraft-Heinz's budget cutting. Convenience store chain Sheetz ended its "smile policy" after his reporting.Before joining Insider in September 2020, he wrote about consumer and retail companies for S&P Global Market Intelligence. He's a graduate of the University of Hawai'i at Mānoa and grew up on the Big Island.Alex lives in the Washington, DC, area, where you can find him studying ancient coins or searching for Civil War artifacts with his metal detector in his free time.Got a tip? Reach out at [email protected] or via encrypted messaging app Signal at +1 (808) 854-4501.
BARCELONA, Spain--(BUSINESS WIRE)--Wallbox (NYSE: WBX), a global provider of electric vehicle charging and energy management solutions, today announced a new partnership with Freenow by Lyft, one of Europe’s leading multi-mobility apps, to support the electrification of taxi operations across key European markets. Through the agreement, Freenow drivers and fleet operators will gain access to exclusive conditions across a selection of Wallbox charging solutions designed for both home and business use.
The program has already launched in Germany, France, the United Kingdom, Ireland and Spain. Through the partnership, Freenow BEV and PHEV taxi drivers and fleet owners will be able to access Wallbox charging solutions tailored to their day-to-day operational needs, whether charging at home or at fleet depots. The offering will include Pulsar Max for individual drivers, as well as Pulsar Pro and eM4 for fleet and shared charging environments.
As taxi and ride-hailing networks across Europe continue to electrify, access to reliable and easy-to-manage charging infrastructure is becoming increasingly important for both independent drivers and fleet operators. Latest data shows that over 60% of vehicles in more than 180 cities in Europe on the Freenow platform are already fully or partially electrified, highlighting the growing momentum behind this transition. By partnering with Freenow, Wallbox is expanding access to charging solutions that can help simplify the shift to electric mobility, while supporting more efficient daily operations for professionals who depend on their vehicles throughout the day.
Ignasi Alastuey, Chief Business Officer at Wallbox, said: “The shift to electric mobility in the taxi sector will depend on making charging simple, accessible and suited to the everyday needs of drivers and fleet operators. At Wallbox, we are focused on helping remove barriers to adoption with charging solutions that are easy to use and designed to support professional mobility. Through this partnership with Freenow, we are making that transition more accessible for drivers across Europe.”
Felix Brand, Chief Strategy Officer at Freenow by Lyft, added: “At Freenow, we are committed to supporting drivers and fleet partners in their transition to electric mobility. Working with Wallbox allows us to offer access to charging solutions that are practical, reliable and adapted to the needs of our driver community, helping make electrification a more viable option across our network.”
Under the agreement, Freenow drivers and fleet operators will benefit from exclusive discounts across the selected Wallbox portfolio. The partnership will also connect them with Wallbox’s local network of certified installation partners, helping ensure a smooth experience from initial interest through installation.
With this collaboration, Wallbox continues to strengthen its position as a partner for the electrification of professional mobility in Europe, supporting a growing range of use cases from individual home charging to more complex fleet charging needs.
About Wallbox
Wallbox is a global technology company, dedicated to changing the way the world uses energy. Wallbox creates advanced electric vehicle charging and energy management systems that redefine the relationship between users and the network. Wallbox goes beyond charging electric vehicles to give users the power to control their consumption, save money and live more sustainably. Wallbox offers a complete portfolio of charging and energy management solutions for residential, semi-public, and public use in more than 100 countries around the world. Founded in 2015 in Barcelona, where the company’s headquarters are located, Wallbox currently has offices across Europe, Asia, and America. For more information, visit www.wallbox.com.
About Freenow by Lyft
Freenow by Lyft is the European taxi app featuring broad multi-mobility options for everyone across 9 European markets and over 180 cities. Millions of passengers can access various mobility services within a single app, including taxis, private hire vehicles, carsharing, car rental, e-scooters, e-bikes, e-mopeds and public transport. With headquarters in Hamburg, Germany, Freenow is led by CEO Thomas Zimmermann.
In July 2025, Freenow was acquired by Lyft, a global mobility platform offering a mix of rideshare, taxis, private hire vehicles, executive chauffeur services, car sharing, bikes, and scooters across 6 continents and thousands of cities. Millions of drivers have chosen to earn on billions of rides. Together, Freenow and Lyft are helping to create a more connected world, with transportation options for everyone.
Visit our website for further information and download the Freenow app.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding Wallbox’s expected future operating results and financial position, growth, profitability and cost optimization, including expected impact of the commercial agreement regarding Wallbox’s renewed capital structure; industry and company growth, and Wallbox’s business strategy and plans, including expected benefits of the commercial launches of the Quasar 2 and Supernova PowerRing and related reinforcement of Wallbox’s sales and service organization. The words “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “focus,” “forecast,” “intend,” “likely,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: Wallbox’s history of operating losses; the adoption and demand for electric vehicles including the success of alternative fuels, changes to rebates, tax credits and the impact of government incentives or reduction thereof; political and economic uncertainty and macroeconomic factors, such as impacts from tariffs and trade barriers, geopolitical conflicts, consumer spending, inflation and foreign exchange rates; the accuracy of Wallbox’s forecasts and projections including those regarding its market opportunity; competition; risks related to losses or disruptions in Wallbox’s supply or manufacturing partners; Wallbox’s reliance on the third-parties outside of its control; risks related to Wallbox’s technology, intellectual property and infrastructure; executive orders and regulatory changes under the U.S. political administration and uncertainty therefrom, as well as the other important factors discussed under the caption “Risk Factors” in Wallbox’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in its other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of Wallbox’s website at investors.wallbox.com. Any such forward-looking statements represent management’s estimates as of the date of this press release. Any forward-looking statement that Wallbox makes in this press release speaks only as of the date of such statement. Except as required by law, Wallbox disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.
The national average for a gallon of regular gasoline hit $4.55 on May 7, 2026 -- up $1.40 from a year ago and at its highest level since the 2022 energy crisis, according to AAA. In California, drivers are paying $6.11 a gallon. 50% of Americans expect prices to keep climbing through 2027, according to a recent Ipsos poll.
Behavior is already shifting. That same survey found 44% of adults have cut back on driving, 34% have changed vacation plans, and where public transit exists, ridership is rising. There was also a 40% jump in carpooling platform rides from February to March alone.
Lyft (LYFT 1.24%) is the direct beneficiary of that shift -- and it's trading like the market hasn't noticed.
Today's Change
(
-1.24
%) $
-0.17
Current Price
$
13.54
Lyft just reported Q1 2026 gross bookings of $4.9 billion, up 19% year over year, with active riders at a record 28.3 million -- the sixth consecutive quarter of double-digit rider growth. Revenue came in at $1.7 billion, up 14%, and trailing-12-month free cash flow crossed $1.1 billion for the first time in company history. When gas is expensive, people abandon solo car trips. Lyft is where those trips go.
CEO David Risher called Q1 results the continuation of a "customer-obsessed comeback," and the metrics back that up. The platform is also deepening its moat through partnerships: nearly 27% of North American rides now tie to a partner arrangement -- an all-time high -- with programs through JPMorgan Chase, DoorDash, and United Airlines driving bookings that originate outside the Lyft app entirely.
Image source: Getty Images.
The part of Lyft that the market is pricing wrong Despite the momentum, Lyft trades near $14 -- roughly 31% below the Wall Street consensus price target of $19.43, and well off its 52-week high of $26. TD Cowen maintains a Buy rating, and the stock trades at a forward P/E about 13.5 -- cheap for a business generating record free cash flow with visible rider growth.
The deeper optionality is Flexdrive -- Lyft's fleet management arm, which operates 24 depots managing roughly 15,000 vehicles across North America. This fall, Lyft will open an 80,000-square-foot purpose-built facility in Nashville to manage Waymo's autonomous vehicle fleet. That is a physical depot already under construction, with a charged customer and a launch date. If robotaxis scale, Lyft earns fees without bearing vehicle costs -- a fundamentally different margin structure from today's driver-dependent model.
It's important to note that Lyft is nowhere close in size to Uber Technologies. Uber is massive. Lyft lacks global scale, and its EPS missed estimates in Q1. The economics of autonomous vehicle fleets remain unproven at scale. Any stall in the rider's growth trajectory would close the gap between the current price and fair value faster than in the bull case.
But the setup right now is clean: gas is expensive, people are driving less, Lyft's core metrics are at records, free cash flow is real, and the stock is below analyst targets. This is a solid long-term buy.
JPMorgan Chase is an advertising partner of Motley Fool Money. Micah Zimmerman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends DoorDash, JPMorgan Chase, Lyft, and Uber Technologies. The Motley Fool has a disclosure policy.
*Stock prices used were the afternoon prices of May 14, 2026. The video was published on May 16, 2026.
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Lyft. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Key Takeaways Uber Q1 2026 EPS of 72 cents beat 70 cents estimate; total gross bookings rose 25% to $53.7B.Uber sees Q2 gross bookings $56.25B-$57.75B, up 18-22% Y/Y on constant currency. Lyft Q1 EPS of 21 cents missed the 31-cents consensus; shares slid on the earnings miss. Uber Technologies (UBER - Free Report) , headquartered in San Francisco, CA, has pursued an aggressive global expansion strategy while broadening its business portfolio. While ride-sharing continues to be its core business, the company has established substantial additional revenue sources through Uber Eats, its food delivery platform, and Uber Freight, a logistics marketplace. This diversified approach reflects Uber’s ambition to evolve into a comprehensive transportation and delivery ecosystem rather than remain solely a ride-hailing company.
Lyft (LYFT - Free Report) , also based in San Francisco, has adopted a more concentrated strategy. The company operates primarily within the United States and remains heavily focused on ride-sharing, placing far less emphasis on diversification. This focused business model allows Lyft to channel resources toward strengthening the core services, although it also reduces exposure to higher-growth segments such as delivery services and international expansion.
Earlier this month, both companies announced their first-quarter 2026 results. Given their contrasting strategic approaches, it is worthwhile to assess which stock offers the more attractive investment opportunity following the latest quarterly earnings reports.
The Case for UBEROn May 6, Uber posted better-than-expected earnings per share for the first quarter of 2026. Moreover, management gave a bullish outlook for bookings, noting that demand remains strong despite geopolitical tensions in the Middle East.
Uber’s earnings per share of 72 cents beat the Zacks Consensus Estimate of 70 cents. The reported figure matched the higher end of the company's guided range of 65-72 cents per share.
Total revenues of $13.2 billion missed the Zacks Consensus Estimate of $13.3 billion. The top line jumped 14.4% year over year on a reported basis and 10% on a constant currency basis.
Despite the crisis in the Middle East, UBER’s Mobility business saw impressive demand, with segmental revenues increasing 5% year over year on a reported basis and 1% on a constant currency basis to $8.2 billion.
Gross bookings from the unit were highly impressive, aiding the first-quarter results. From the Mobility segment in the March quarter, gross bookings increased 20% year over year on a constant-currency basis to $26.4 billion.
Uber’s Delivery business also performed well in the quarter, with segmental revenues growing 23% year over year on a constant-currency basis. Gross bookings from the Delivery segment in the first quarter rose 23% year over year on a constant-currency basis to $26 billion. Total gross bookings jumped 25% to $53.7 billion, ahead of the Zacks Consensus Estimate of $52.9 billion.
Uber saw a 17% increase in its monthly active platform consumers to 199 million users in the March quarter. The platform recorded 3.64 billion trips, marking a 20% year-over-year rise, driven by both ride-hailing and delivery services.
The earnings beat by Uber in the March quarter meant that its impressive earnings surprise record continued. Uber has reported a positive earnings surprise in three of the past four quarters (and the metric was negative in the other quarter). The average beat is 89.6%.
More than the first-quarter numbers, it was the second-quarter gross bookings forecast that pleased investors. Shares of the ride-hailing giant have gained 3% so far post the earnings release.
Despite the ongoing tensions in the Middle East and the resultant fuel price spike, gross bookings are projected in the range of $56.25-$57.75 billion, highlighting growth of 18% to 22% year over year on a constant-currency basis. The outlook assumes a roughly 2 percentage-point currency tailwind to total reported year-over-year growth.
Adding to the bullishness, management expects June quarter earnings to grow in the 31-38% band year over year. As a result, second-quarter earnings per share are expected in the 78-82 cents band.
Despite the uptick, following the first-quarter earnings beat, Uber’s price performance is disappointing so far this year, lagging the Zacks Internet-Services industry. Uber’s shares have dropped primarily on concerns regarding competition in the robotaxi and autonomous driving space.
The Case for LYFTOn May 7, Lyft released its first-quarter 2026 earnings report. Quarterly earnings per share of 21 cents missed the Zacks Consensus Estimate of 31 cents but increased 10.5% year over year. Revenues of $1.65 billion beat the Zacks Consensus Estimate by 1.8% and grew 13.8% year over year.
The miss by Lyft in the March quarter meant that its unimpressive earnings surprise record continued. Lyft has reported a negative earnings surprise in each of the past four quarters. The average miss is 53.3%.
In the March quarter, gross bookings increased 19% year over year to $4.9 billion. This was the 20th consecutive quarter where Lyft demonstrated double-digit year-on-year growth in the key metric, demonstrating the resilience and momentum of its customer-friendly strategy. Active Riders increased 17% year over year to 28.3 million.
For the second quarter of 2026, Lyft anticipates gross bookings to grow 18-21% year over year, reaching $5.3-$5.43 billion. The company expects adjusted EBITDA to be in the band of $160 million and $180 million. Adjusted EBITDA margin (calculated as a percentage of Gross Bookings) for the June quarter is anticipated to be in the range of 3-3.3%.
The loss, however, reported in the quarter seems to have disappointed investors, resulting in the stock declining sharply since the first-quarter earnings release. In fact, Lyft’s shares have performed worse than Uber so far this year.
YTD Price Comparison
Image Source: Zacks Investment Research
Lyft More Attractive Than Uber on Valuation FrontLyft is trading at a forward sales multiple of 0.65X, comparing favorably to Uber’s 2.5X. LYFT has a Value Score of B, compared with UBER’s C.
Image Source: Zacks Investment Research
End NoteUber’s strong focus on strategic diversification and shareholder-friendly initiatives remains a key advantage. Supported by a solid market capitalization of $152.85 billion, the company appears well-equipped to withstand the current macroeconomic uncertainty. Uber’s diversification efforts — including acquisitions, global expansion and innovative service offerings — have been instrumental in mitigating risks and strengthening its competitive position.
It is true that Lyft, like Uber, continues to benefit from healthy gross bookings. However, Lyft’s weaker earnings surprise and relatively subdued stock performance compared with Uber place it at a disadvantage. Based on our analysis, Uber clearly stands out as the stronger contender in this comparison with Lyft. Therefore, it is reasonable to conclude that Uber is better positioned than Lyft following their respective first-quarter 2026 earnings releases.
Lyft currently carries a Zacks Rank #5 (Strong Sell) and Uber has a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lyft appears deeply undervalued, with a reverse DCF implying negative 26% free cash flow growth needed to justify current prices. LYFT's fundamentals show a non-GAAP P/E of 10.55, a GAAP P/E of 1.87, 10.55% revenue growth, and a strong ~44% net income margin. Autonomous vehicles pose a long-term threat, but the transition is expected to be gradual, and LYFT could become an acquisition target.
On May 22, 2026, Lyft Inc LYFT shares rose 3.1% today, currently priced at $13.90. The stock has seen a 52-week range between $12.46 and $25.54, reflecting significant volatility in the market.
GF Value™ verdict: Current price is $13.90, with a GF Value™ of $17.14, indicating an 18.9% undervaluation. GF Score™ of 77/100 suggests the stock is rated as above average. Notable signal: Insiders sold $0.8M worth of shares in the last 3 months, with no buying activity reported. Is LYFT Overvalued or Undervalued? Currently, Lyft Inc's shares are trading at $13.90, compared to the GF Value™ estimate of $17.14. This indicates that the stock is undervalued by approximately 18.9%, providing a margin of safety for potential investors. The GF Valuation label classifies LYFT as modestly undervalued, suggesting that there may be an opportunity for growth if market conditions improve.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. While the undervaluation presents a potential opportunity, investors should be cautious considering the company's financial strength and recent insider selling activity, which may indicate some underlying concerns.
How Does LYFT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 2.0x 60.9x Forward P/E N/A 23.0x The current P/E (TTM) of 2.0x is significantly below its 5-year median P/E of 60.9x, indicating that the stock is trading well below its historical valuation metrics. This analysis aligns with the GF Value™ verdict, reinforcing the notion that LYFT is undervalued based on its historical performance.
What Does LYFT's GF Score™ Tell Us? Metric Rating GF Score™ 77/100 Financial Strength 5/10 Profitability 4/10 Growth 8/10 Valuation 8/10 Momentum 5/10 The GF Score™ of 77/100 indicates that Lyft is rated above average, with strong growth and valuation ranks of 8/10. However, the financial strength and profitability ranks are relatively weaker at 5/10 and 4/10, respectively, suggesting that while the potential for growth is robust, the company's current financial health may present challenges.
What Are Insiders Doing with LYFT Stock? In the past three months, insiders have sold $0.8 million worth of LYFT shares, with no buying activity reported. This trend of selling may suggest that insiders lack confidence in the company's short-term prospects, which could be a point of concern for potential investors.
What This Means for Investors Based on the assessment of LYFT's current price in relation to its GF Value™, the stock is considered undervalued. However, investors should remain cautious due to insider selling and the company's moderate financial strength. It is essential to conduct thorough research before making any investment decisions.
For the complete analysis, visit the Lyft Inc LYFT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is LYFT's GF Score™?
LYFT's GF Score™ is 77/100, indicating that the stock is ranked above average based on key financial metrics.
Is LYFT overvalued or undervalued?
LYFT is currently undervalued, with a GF Value™ of $17.14 compared to its current price of $13.90, suggesting potential for growth.
What is LYFT's P/E ratio?
LYFT's P/E ratio is 2.0x, which is significantly lower than its 5-year median P/E of 60.9x, indicating that it is trading well below its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Item 1 of 2 A traveler walks into the Uber pickup zone at the Los Angeles International Airport's LAX-it pick up terminal in Los Angeles, California, U.S., March 10, 2026. REUTERS/Caroline Brehman
[1/2]A traveler walks into the Uber pickup zone at the Los Angeles International Airport's LAX-it pick up terminal in Los Angeles, California, U.S., March 10, 2026. REUTERS/Caroline Brehman Purchase Licensing Rights, opens new tab
SummaryCompaniesApp Drivers Union certified to represent 70,000 Massachusetts ride-share driversUnionization follows 2024 ballot measure allowing bargaining for gig workersSimilar unionization efforts under way in other statesBOSTON, May 26 (Reuters) - Ride-share drivers for app-based companies such as Uber (UBER.N), opens new tab and Lyft (LYFT.O), opens new tab have unionized in Massachusetts, forming what state officials and labor leaders said was the first officially recognized organization in the U.S. to represent such gig workers.
The newly formed App Drivers Union received certification, opens new tab from the Massachusetts Department of Labor Relations on Friday to represent nearly 70,000 ride-share drivers operating as independent contractors in the state.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
"It changes the game for ride-share workers across this country," Massachusetts Governor Maura Healey, a Democrat, said at a rally with drivers and labor activists in Boston on Tuesday.
The certification occurred after voters in November 2024 approved a ballot measure that created a novel framework to allow drivers for companies like Uber and Lyft to organize and bargain collectively over pay and benefits.
That vote followed a years-long, nationwide battle over whether ride-share drivers should be considered independent contractors or employees entitled to benefits and wage protections.
Drivers for Uber and Lyft do not have the right to organize under the National Labor Relations Act, a federal law that covers only traditional employees.
But under the state law, drivers could form a union after collecting signatures from at least 25% of active drivers in Massachusetts - a condition that was met by union supporters. The union is backed by 32BJ SEIU, an affiliate of the Service Employees International Union, and the International Association of Machinists and Aerospace Workers.
"The workers who built these billion-dollar corporations deserve a union contract and a seat at the table," IAM President Brian Bryant said at Tuesday's rally.
He and other union leaders held up Massachusetts as a key labor victory as unionization efforts mount in other states.
In California, ride-share drivers gained the right to unionize under legislation signed into law in October by Democratic Governor Gavin Newsom. Similar legislation is pending in Illinois.
Lyft and Uber did not campaign against the Massachusetts ballot measure. Lyft said on Tuesday it was committed to engaging in good faith as the Massachusetts process moves forward.
"Lyft does well when drivers do well, and we'll stay focused on helping drivers succeed while keeping rideshare affordable and dependable for everyone who counts on it," Lyft said in a statement.
Uber did not respond to a request for comment.
In the months before the 2024 vote, Massachusetts Attorney General Andrea Joy Campbell secured a settlement with Uber and Lyft requiring them to adopt a $32.50 hourly minimum pay standard for Massachusetts drivers and pay $175 million to resolve claims they had improperly treated drivers as independent contractors, rather than employees, under state law.
Reporting by Nate Raymond in Boston; Editing by Matthew Lewis
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Nate Raymond reports on the federal judiciary and litigation. He can be reached at [email protected].
These ride-sharing leaders are making moves amid massive changes in transportation driven by artificial intelligence (AI) and self-driving technology. Uber Technologies (UBER 1.25%) and Lyft (LYFT 1.24%) are posting strong growth for their services, but the head-to-head comparison of recent growth and revenue size may give investors a big clue as to which company is best positioned to win.
Uber Technologies: Recent Revenue TrendsUber Technologies operates a global technology network that connects consumers with independent providers for ridesharing, restaurant meal delivery, and freight transportation services.
The company announced a 21% year-over-year increase in revenue for the first quarter, along with new initiatives in robotaxis and expansion into hotel bookings. Uber has scaled its ridesharing platform into a profitable business, with operating profit reaching $1.9 billion in the quarter.
Today's Change
(
-1.25
%) $
-0.87
Current Price
$
68.68
Lyft: Steady GrowthLyft operates a multimodal transportation network that offers riders personalized, on-demand access to ridesharing, flexible car rentals, and shared bikes across the United States and Canada.
The company posted a 14% year-over-year increase in revenue in the first quarter. It recently announced an acquisition of Gett U.K., helping Lyft expand its operations into higher-value segments of the London market. It’s not as profitable as Uber, reporting an operating loss of $5.3 million last quarter.
Today's Change
(
-1.24
%) $
-0.17
Current Price
$
13.54
Why Revenue Matters for Retail InvestorsRevenue is the most fundamental measure of a company’s performance. Changes over time, particularly when comparing two companies in the same industry, can provide valuable insights about a company’s competitive position and ability to reach new customers.
Foolish TakeThere is a clear contrast between Uber and Lyft. While Uber experiences greater quarterly revenue volatility, it is growing faster off a larger revenue base.
Uber benefits from greater scale and global reach, allowing it to generate over $53 billion in annual revenue, compared to Lyft’s $6.5 billion.
Both companies are pursuing every opportunity to position themselves for more growth through partnerships. The stakes are massive as the future of transportation is in AI-powered self-driving vehicles.
For Lyft, Google’s Waymo is set to integrate with the Lyft app later this year. However, Uber boasts of a large network of 30 partners that will help it expand robotaxi services to 15 cities by the end of 2026.
Lyft expects continued growth this year, with gross bookings expected to accelerate in the near term. Investors will want to keep a close eye on whether it can accelerate its growth and narrow the gap with Uber. Given Lyft’s discounted share price, it may offer more upside from these levels than Uber, but this will heavily depend on execution and its ability to accelerate revenue growth.
Lyft trades at a deep discount, with a ~4x P/FCF multiple, despite double-digit growth and robust cash generation. Fears that autonomous vehicles will disrupt ridesharing are overstated; AVs are more likely to expand the total addressable market than displace platforms. Utilization challenges and customer acquisition costs favor aggregators like LYFT, as AV fleets struggle to match dynamic human-supply networks.
On June 10, 2026, Lyft Inc LYFT shares fell 3.4% to $13.39, continuing a downward trend that has seen the stock decrease by 30.9% year-to-date. The stock has traded within a 52-week range of $12.46 to $25.54, indicating significant volatility over the past year.
GF Value™ verdict: Current price at $13.39 vs GF Value™ of $17.30, representing a 22.6% undervaluation.GF Score™: 76/100, indicating above-average potential for long-term returns.Notable signal: Insiders sold $0.8 million in stock over the last three months with no buying activity. Is LYFT Overvalued or Undervalued? With a current price of $13.39 and a GF Value™ of $17.30, Lyft is estimated to be 22.6% undervalued. This margin of safety may present an attractive opportunity for investors who believe in the company's long-term prospects. However, the GF Valuation label indicates that the stock is considered "Modestly Undervalued," which suggests a cautious approach is warranted. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the undervaluation could imply potential upside, investors should be cautious due to the stock's recent performance and insider selling activity, which may signal a lack of confidence among those closest to the company.
How Does LYFT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 1.9x 60.0x Forward P/E 23.4x N/A Lyft's current P/E ratio of 1.9x is significantly below its 5-year median P/E of 60.0x and indicates that the stock is trading far below its historical valuation levels. This analysis agrees with the GF Value™ verdict, reinforcing the notion that Lyft may be undervalued in the current market environment.
What Does LYFT's GF Score™ Tell Us? Metric Rating GF Score™ 76 Financial Strength 5/10 Profitability 4/10 Growth 8/10 Valuation 8/10 Momentum 5/10 The GF Score™ of 76/100 suggests that Lyft demonstrates above-average potential for long-term returns. The strongest area is growth, with a ranking of 8/10, indicating robust growth prospects. Conversely, the weakest area is profitability, scored at 4/10, which may raise concerns about the company's ability to sustain its growth amidst current financial challenges.
What Are Insiders Doing with LYFT Stock? In the last three months, insiders sold $0.8 million worth of Lyft stock with no buying activity reported. This trend of selling may indicate a lack of confidence from insiders regarding the future performance of the company. Such actions can often be a red flag for investors, suggesting that those with the most insight into the company are not optimistic about its near-term prospects.
What This Means for Investors Based on the GF Value™ assessment, Lyft Inc is currently undervalued. The substantial difference between its market price and intrinsic value suggests potential for appreciation, but caution is warranted given the recent insider selling and the company's profitability challenges.
For the complete analysis, visit the Lyft Inc LYFT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is LYFT's GF Score™?
LYFT's GF Score™ is 76/100, indicating above-average potential for long-term returns based on key fundamental metrics.
Is LYFT overvalued or undervalued?
LYFT is currently undervalued, with its market price of $13.39 being 22.6% below its GF Value™ of $17.30.
What is LYFT's P/E ratio?
LYFT's P/E ratio is 1.9x, which is significantly lower than its 5-year median P/E of 60.0x, indicating it is trading well below its historical valuation levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Lyft (LYFT - Free Report) closed the most recent trading day at $13.71, moving +2.39% from the previous trading session. The stock outpaced the S&P 500's daily gain of 1.75%. Meanwhile, the Dow experienced a rise of 1.86%, and the technology-dominated Nasdaq saw an increase of 2.54%.
Coming into today, shares of the ride-hailing company had lost 2.12% in the past month. In that same time, the Computer and Technology sector lost 3.11%, while the S&P 500 lost 1.63%.
Market participants will be closely following the financial results of Lyft in its upcoming release. On that day, Lyft is projected to report earnings of $0.39 per share, which would represent year-over-year growth of 56%. Alongside, our most recent consensus estimate is anticipating revenue of $1.8 billion, indicating a 13.58% upward movement from the same quarter last year.
LYFT's full-year Zacks Consensus Estimates are calling for earnings of $1.57 per share and revenue of $7.28 billion. These results would represent year-over-year changes of +227.08% and +15.3%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Lyft. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.94% higher. At present, Lyft boasts a Zacks Rank of #3 (Hold).
Investors should also note Lyft's current valuation metrics, including its Forward P/E ratio of 8.53. This signifies a discount in comparison to the average Forward P/E of 15.6 for its industry.
Investors should also note that LYFT has a PEG ratio of 0.35 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Internet - Services industry had an average PEG ratio of 1.7 as trading concluded yesterday.
The Internet - Services industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 175, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Bristol Myers Squibb (BMY +0.40%) is a well-respected pharmaceutical company. Technically, it was created in 1989 through the merger of two other companies, but both of those businesses were founded in the 1800s. It is a proven survivor that clearly knows how to navigate the highly complex and competitive drug industry. And the stock looks cheap today. But is it really as cheap as it looks?
Bristol Myers Squibb's value appeal Bristol Myers Squibb's price-to-earnings ratio is currently sitting around 16x. That's well below the S&P 500's (^GSPC +0.50%) 27x and the pharmaceutical industry's 24x average. Meanwhile, Bristol Myers Squibb's dividend yield is a highly attractive 4.4%. By comparison, the S&P 500 index has a yield of 1.1%, and the average drug maker's yield is around 1.7%.
Image source: Getty Images.
It would be understandable if value investors jumped aboard. For dividend investors attracted to the lofty yield, the company's 70% payout ratio is a bit high but not unreasonably so. Still, you should ask yourself why the company looks attractively priced before you buy it.
The fly in Bristol Myers Squibb's ointment Bristol Myers Squibb isn't likely to go out of business anytime soon. If your investment horizon is decades long, you may want to own this stock today, given its attractive valuation metrics. However, you'll have to be prepared for some uncertainty through at least the end of 2028. That's because the company has key drugs with upcoming patent expirations. Revlimid and Pomalyst, both cancer drugs, will get hit in 2026, and cardiovascular drug Eliquis, which is marketed with competitor Pfizer (PFE +0.15%), is set to face generic competition in 2028.
Today's Change
(
0.40
%) $
0.23
Current Price
$
57.13
To be fair, the company has been working on its drug pipeline. But research and development don't work on a timeline, while patent expirations do. There could be a timing mismatch that leaves Bristol Myers Squibb's top and bottom lines under material pressure in the near term. So, the stock looks like it is a bargain, but there's a reason for the discounted price.
Bristol Myers Squibb is a long-term commitment The pharmaceutical business is intensely competitive. Bristol Myers Squibb has proven it knows how to survive in the long term, and the price has some value and income appeal today. However, it may not be as cheap as it seems when you factor in near-term patent headwinds. If you are hoping to make a quick buck, you should probably look elsewhere.
That said, if your plan is to hold the stock for decades, Bristol Myers Squibb may still be worth buying. After all, it is probably better to buy a good company at an attractive price than to try to time the bottom with every purchase, which is a virtually impossible task to do consistently.
Bristol Myers Squibb is mispriced as a melting ice cube, despite its Growth Portfolio surpassing Legacy revenues in Q1 2026. BMY's pipeline offers four near-term catalysts—including iberdomide, mezigdomide, milvexian, and Cobenfy—that could force a re-rating within seven months. Even using bearish consensus forecasts, BMY's DCF supports a $68.5/share valuation, about 20% above current levels, with downside well protected.
Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026
SystImmune and Bristol Myers Squibb’s potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate has now demonstrated clinical benefit in three Phase 3 trials in China, underscoring its broad therapeutic potential in multiple tumor types
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive results from prespecified interim analyses of two Phase 3 studies evaluating izalontamab brengitecan (iza-bren), an investigational and potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC). The studies demonstrated iza-bren achieved statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC; PANKU-Breast02/BL-B01D1-307) and recurrent or metastatic esophageal squamous cell carcinoma (ESCC; PANKU-Esophagus01/BL-B01D1-305). These data, presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, support iza-bren’s potential as a new standard of care in these challenging cancer types.
$BMY and SystImmune announce new data for a dual-targeted EGFRxHER3 bispecific antibody-drug conjugate in triple negative breast cancer and metastatic esophageal squamous cell carcinoma at #ASCO26.
Share Iza-bren has now shown clinical benefit in three Phase 3 trials, underscoring its broad therapeutic potential. PANKU-Breast02 is the first Phase 3 study of a bispecific ADC to report positive results for dual primary endpoints of both PFS and OS in TNBC, while PANKU-Esophagus01 marks the first Phase 3 trial of a bispecific ADC in esophageal cancer to report positive dual primary endpoints of both PFS and OS. Iza-bren previously demonstrated positive phase 3 results in recurrent or metastatic nasopharyngeal carcinoma (NPC), presented at ESMO 2025.
“As a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate, iza-bren has now shown significant clinical benefit in three Phase 3 trials in different cancer types, and the strength of these data presented at ASCO further reinforce the value iza-bren can deliver over current standards of care,” said Dr. Yi Zhu, chief executive officer of Biokin. “We are proud to share these results as we continue to evaluate iza-bren to unlock the full potential of this dual mechanism of action to improve outcomes for patients in need.”
“Iza-bren can address a critical gap for patients who develop resistance or experience disease progression after prior therapies and may also hold potential in earlier lines of therapy,” said Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “We have a broad development program for iza-bren and believe it has the potential to be a cornerstone treatment in a number of different cancers and easily combined with other therapies.”
Results from the Interim Analysis of PANKU-Breast02 (BL-B01D1-307)
The Phase 3 PANKU-Breast02 trial evaluated iza-bren in patients with unresectable locally advanced or metastatic TNBC whose disease progressed following 1-2 prior lines of systemic therapy for advanced disease, including prior taxane therapy. Patients were randomized 1:1 to receive iza-bren (n=207) or physician’s choice of chemotherapy (TPC; n=211), which included eribulin, capecitabine, gemcitabine, or vinorelbine. The study met both dual primary endpoints at a prespecified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in OS and BICR-assessed PFS with iza-bren compared to TPC.
With a median follow-up of 11 months, median OS was 15.9 months with iza-bren vs. 12.5 months with TPC (HR: 0.60; 95% CI: 0.42-0.85; p=0.0019) Median PFS by Blinded Independent Central Review (BICR) was 8.5 months with iza-bren vs. 3.1 months with TPC (HR: 0.29; 95% CI: 0.22-0.38; p<0.0001) The confirmed objective response rate (ORR) assessed by BICR was 51.7% with iza-bren compared to 20.5% with TPC (odds ratio, 4.3; 95% CI: 2.8-6.7) “While there have been significant advancements in breast cancer treatment, advanced triple-negative breast cancer has remained a challenge, with patients facing poor outcomes,” said Dr. Jiong Wu, Fudan University Shanghai Cancer Center. “These results highlight the potential for iza-bren to be a new standard of care as the first bispecific ADC to show improved progression-free and overall survival in a Phase 3 study in this patient population.”
Iza-bren showed a manageable safety profile in this heavily pre-treated patient population, with no new safety signals observed. Grade >3 treatment-emergent adverse events (TEAEs) were predominantly hematologic toxicities and consistent with the known safety profile of iza-bren. Any grade interstitial lung disease (ILD) was reported in 3 (1.4%; 1 case of grade 1 and 2 cases of grade 2) patients treated with iza-bren and 0 patients treated with TPC. Treatment discontinuation due to TEAEs occurred in 4 (1.9%) patients treated with iza-bren and 1 (0.5%) patients treated with TPC.
Results from the Interim Analysis of PANKU-Esophagus01 (BL-B01D1-305)
The Phase 3 PANKU-Esophagus01 trial evaluated iza-bren in patients with recurrent or metastatic esophageal squamous cell carcinoma who had progressed after first-line treatment with a PD-1/PD-L1 inhibitor plus platinum-based chemotherapy (n=249) compared to chemotherapy of physician’s choice (n=248). Results from the interim analysis show iza-bren demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of OS and BICR-assessed PFS.
Median OS was 9.8 months with iza-bren vs. 7.2 months with chemotherapy (HR: 0.64; 95% CI: 0.49-0.83; p=0.0004). Median PFS by BICR was 4.2 months with iza-bren vs. 2.0 months with chemotherapy (HR:0.50; 95% CI: 0.40-0.63; p<0.0001). Iza-bren also demonstrated an improvement in responses with an ORR by BICR of 35.3% compared to 13.1% with chemotherapy. “Metastatic esophageal squamous cell carcinoma is an aggressive disease with a five-year survival rate of less than 5%, and there remains a critical unmet need for treatment options after first-line immunotherapy and chemotherapy,” said Dr. Lin Shen, Peking University Cancer Hospital and Institute. “As the first Phase 3 clinical trial of a novel EGFRxHER3 bispecific antibody-drug conjugate to report positive data in this patient population, these results show the potential for iza-bren to set a new benchmark in significantly extending survival for patients with recurrent or metastatic esophageal squamous cell carcinoma.”
Iza-bren also showed a manageable safety profile in this patient population. Grade >3 treatment-related adverse events (TRAEs), which were predominantly hematologic toxicities, occurred in 85.1% of patients treated with iza-bren and 60.2% of patients who received chemotherapy. TRAEs that led to treatment discontinuation occurred in 2% of patients treated with iza-bren and 3.3% treated with chemotherapy. Treatment-related deaths occurred in 1.2% of patients treated with iza-bren and 1.6% of patients treated with chemotherapy. The rates of all grades and grade >3 ILD were low in the iza-bren arm (1.6%/0.8%) and the chemotherapy arm (0.4%/0.4%).
A New Drug Application for iza-bren for the treatment of recurrent or metastatic esophageal squamous cell carcinoma has been accepted by the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) and included in the priority review process.
The PANKU-Breast02 and PANKU-Esophagus01 studies are sponsored by SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), in Mainland China. Outside of China, iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.
About iza-bren
Iza-bren (BL-B01D1) is a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren's dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren's therapeutic novel Topo1i payload is released causing cytotoxic stress that leads to cancer cell death.
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
SystImmune Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential clinical benefits of iza-bren, the timing and outcomes of regulatory interactions, and the future development and commercialization of iza-bren. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. SystImmune undertakes no obligation to update any forward-looking statements contained herein, except as required by law.
Bristol Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that izalontamab brengitecan (iza-bren) may not achieve its primary study endpoints or receive regulatory approvals for the indications described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such treatment for such indication will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting legacy drug declines and demonstrating early-stage growth runway. Upcoming pivotal clinical readouts in H2 2026, including milvexian and Cobenfy, are set to define BMY's long-term growth trajectory.
Over the past few years, Bristol Myers Squibb (BMY +0.40%) and Pfizer (PFE +0.15%), have underperformed broader equities. However, throughout it all, they have maintained their dividend programs intact and currently boast high yields. Bristol Myers' forward yield is a healthy 4.4%, while Pfizer's is even juicier at 6.6%. Neither company is out of the woods yet, though, as both still have challenges ahead, notably patent cliffs. Which one is the safer bet today for dividend seekers? Let's find out.
Image source: The Motley Fool.
The case for Bristol Myers Squibb Bristol Myers will lose patent exclusivity for Opdivo -- a cancer medicine -- and Eliquis, an anticoagulant it co-markets with Pfizer, by the end of the decade. These two are among the company's best-selling drugs. However, Bristol Myers could overcome these obstacles. The drugmaker's newer, subcutaneous formulation of Opdivo will help attract many older patients and offset losses from biosimilar competition, as it is much easier and faster to administer while still being about as effective.
Today's Change
(
0.40
%) $
0.23
Current Price
$
57.13
Bristol Myers is also working on a next-gen anticoagulant, milvexian. This medicine could address a key risk of traditional blood thinners, bleeding, and target many patients who are undertreated due to this potential side effect. Overall, Bristol Myers has a deep pipeline across oncology, immunology, and other therapeutic areas. The company also has a portfolio of newer drugs, some of which, like Reblozyl for anemia in patients with beta-thalassemia, are posting strong sales growth.
Lastly, Bristol Myers has increased its dividends by 65.8% over the past decade. The company still looks like a top pick for dividend seekers.
The case for Pfizer Besides Eliquis, Pfizer will lose patent exclusivity for other medicines by the end of the decade, including its cancer drug Ibrance. However, the company has newer products that are performing well. One of them is Abrysvo, a vaccine for the respiratory syncytial virus. Pfizer also has a deep pipeline that should yield tangible results over the next few years. The company plans to launch about 20 pivotal studies this year, after starting quite a few in 2025.
Today's Change
(
0.15
%) $
0.04
Current Price
$
26.21
Some of Pfizer's candidates look promising. The company's investigational weight loss medicine, MET-097i, is one of them. Another is Pfizer's next-gen cancer drug, PF'4404. Provided Pfizer can make solid progress with these programs (and others), the company's shares could recover. Lastly, Pfizer continues to increase its dividend, which is up 51.3% over the past 10 years. The stock may not have performed well over the last half-decade, but it could handsomely reward patient investors who stick with it for the long term.
Which is the better buy Between these two stocks, I would give Bristol Myers a slight edge right now, as its newer product portfolio looks better than Pfizer's. Bristol Myers also seems more prepared to overcome upcoming patent cliffs, especially that of Opdivo, thanks to the newer version of the drug. Further, Bristol Myers has grown its dividend faster over the past decade. Overall, it looks like a better income stock. However, those on the market for attractive, blue chip dividend stocks cannot go wrong with either company.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical trial. This trial evaluates pumitamig (BNT327/BMS986545), an investigational PD-L1/VEGF-A bispecific antibody, being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other potential treatment options in advanced renal cell carcinoma (RCC).
As part of this clinical trial collaboration, casdatifan combinations will be added as two new arms of ROSETTA RCC-208. Each company will retain development and commercial rights to their respective assets, and the agreement is mutually non-exclusive.
"We believe casdatifan can transform the treatment paradigm in kidney cancer, and our development strategy is designed to generate evidence needed to establish casdatifan as a backbone therapy so that every patient has the opportunity to benefit from casdatifan across each line of therapy," said Terry Rosen, Ph.D., chief executive officer of Arcus. "HIF-2a inhibition, PD-L1 and VEGF-A blockade are validated mechanisms in the treatment of kidney cancer with a strong biologic rationale for combination. This strategic collaboration with BMS is a top priority for Arcus in order to potentially deliver an additional effective TKI-free option in the first-line setting."
This collaboration is part of Arcus’s holistic development strategy that is intended to provide physicians and patients with: 1) a casdatifan-based and only HIF-2a inhibitor-inclusive TKI-sparing first-line treatment; 2) a casdatifan-based TKI-inclusive first-line regimen; 3) a second-line HIF-2a inhibitor treatment that builds on the second-line standard-of-care TKI, cabozantinib; and 4) a late-line therapy that has been clinically validated to also provide benefit in patients previously treated with a HIF-2a inhibitor-based therapy.
About Casdatifan (AB521)
Casdatifan is a small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2a), a master switch that turns on hundreds of genes in response to low oxygen levels. In a majority of people with the most common form of kidney cancer (clear cell renal cell carcinoma; ccRCC), genetic anomalies result in the dysregulation of this master switch and transformation of normal kidney cells into cancerous ones.
Casdatifan was designed to provide deep and durable inhibition of the HIF-2a pathway. Early clinical studies have shown high response rates and a low primary progression rate relative to clinical benchmarks, warranting further investigation in late-stage studies. Casdatifan, which is administered in pill form once daily, has a safety profile that allows it to be investigated in combination with other treatments.
The casdatifan development strategy is designed to generate evidence needed to establish casdatifan as a backbone therapy so that every ccRCC patient has the opportunity to benefit from casdatifan across each line of therapy. In addition to partner-operationalized studies, Arcus is investigating casdatifan across multiple cohorts in the ARC-20 platform study, alone and in combination with other potential new treatment options, including in the:
First-line setting with cohorts evaluating casdatifan plus zimberelimab, an anti-PD-1 (ongoing); and casdatifan plus zimberelimab and ipilimumab, an anti-CTLA-4 (ongoing) Second-line setting with a cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients (ongoing) Late-line setting with a cohort evaluating casdatifan plus a TKI in both HIF-2a inhibitor-experienced and HIF-2a inhibitor-naive patients (planned) Arcus is also enrolling patients for PEAK-1, the global Phase 3 study evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced metastatic ccRCC. Arcus expects to complete enrollment in PEAK-1 and to initiate a Phase 3 study in first-line metastatic ccRCC by year-end 2026.
Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. Taiho has development and commercial rights in Japan and other countries in Asia, excluding China. Arcus Biosciences holds full rights to casdatifan everywhere else globally.
About Pumitamig (BNT327/BMS986545)
Pumitamig is a novel investigational bispecific antibody, jointly developed by BioNTech and BMS, combining two complementary, validated mechanisms in oncology into one single molecule. Pumitamig combines PD-L1 checkpoint inhibition aimed at restoring T cells’ ability to recognize and destroy tumor cells with the neutralization of VEGF-A. BioNTech and BMS are currently advancing pumitamig in a broad clinical trial program with more than 20 clinical trials currently ongoing or planned to evaluate pumitamig either as a monotherapy or in combination with other treatment modalities targeting different oncogenic pathways in more than 10 solid tumor indications.
About Kidney Cancer
According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,450 Americans will be diagnosed with kidney cancer in 2026. ccRCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for kidney cancer is high; for patients with advanced or late-stage metastatic kidney cancer, however, the five-year survival rate is only 19%. For metastatic kidney cancer, targeted drug therapies are one of the main treatment options.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Arcus Forward-Looking Statements
This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential of casdatifan and pumitamig to achieve more sustained tumor control and deliver a TKI-free option in the first-line setting, statements regarding Arcus’s development strategies and plans, and the timing and achievement of milestones, including the completion of enrollment in PEAK-1 and the initiation of a Phase 3 study in 1L metastatic ccRCC. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks associated with: managing Arcus’s collaborations; risks associated with manufacturing or supplying casdatifan; the unexpected emergence of adverse events or other undesirable side effects with casdatifan or casdatifan-based combinations; changes in the competitive landscape for Arcus’s programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the “Risk Factors” section of Arcus’s most recent periodic report filed with the U.S. Securities and Exchange Commission (SEC) and in other filings that Arcus makes with the SEC from time to time, which are available at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release, except to the extent required by law.
The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.
Bristol Myers Squibb (BMY - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this biopharmaceutical company have returned -4.4% over the past month versus the Zacks S&P 500 composite's +5.4% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has lost 2.9% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Bristol Myers is expected to post earnings of $1.61 per share, indicating a change of +10.3% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.5% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $6.32 points to a change of +2.8% from the prior year. Over the last 30 days, this estimate has changed +0.4%.
For the next fiscal year, the consensus earnings estimate of $6.06 indicates a change of -4.2% from what Bristol Myers is expected to report a year ago. Over the past month, the estimate has changed +0.1%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Bristol Myers.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Bristol Myers, the consensus sales estimate for the current quarter of $11.7 billion indicates a year-over-year change of -4.6%. For the current and next fiscal years, $47.39 billion and $46.15 billion estimates indicate -1.7% and -2.6% changes, respectively.
Last Reported Results and Surprise HistoryBristol Myers reported revenues of $11.49 billion in the last reported quarter, representing a year-over-year change of +2.6%. EPS of $1.58 for the same period compares with $1.8 a year ago.
Compared to the Zacks Consensus Estimate of $10.92 billion, the reported revenues represent a surprise of +5.25%. The EPS surprise was +9.72%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Bristol Myers is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Bristol Myers. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
When it comes to pharmaceutical stocks and yield, Bristol Myers Squibb (BMY +0.40%) and Pfizer (PFE +0.15%) stand out. However, when deciding which of the two is the better high-yield dividend stock, you need to consider numerous criteria, not just the raw yield itself.
When it comes to today's yield, Pfizer is the clear victor. However, when considering whether the higher yield is sustainable, factors such as dividend payout ratios and earnings forecasts start to cast doubt.
With this in mind, let's examine the dividend health of both companies to get a better idea of which of the two is the better choice for income-focused long-term investors.
Image source: Getty Images.
At current prices, Bristol Myers Squibb has a forward dividend yield of around 4.6%. This clearly trails Pfizer's forward yield, which currently comes in at 6.7%. However, the fact that Pfizer's forward yield is so high, especially for a healthcare stock, should signal to you that the market has its own concerns about dividend durability.
Today's Change
(
0.40
%) $
0.23
Current Price
$
57.13
This should be apparent to you as well, once you dive into dividend-related metrics such as each stock's payout ratio. Bristol Myers Squibb has a payout ratio of around 40%, whereas Pfizer's payout ratio is over 60%. In other words, while the former's payout ratio is within the healthy range, Pfizer's payout ratio puts it on the cusp of being too high to be sustainable over the long term.
Today's Change
(
0.15
%) $
0.04
Current Price
$
26.21
At this level, Pfizer generates enough earnings to sustain the dividend, but with so much cash flowing out as dividends, this leaves less capital to pay down debt, fund organic growth, or make new acquisitions. Besides the payout ratio metric, Bristol Myers Squibb also beats Pfizer on dividend growth. Both companies have a similar number of years of consecutive dividend growth.
Bristol Myers Squibb has increased its dividend 18 years in a row, while Pfizer has grown its dividend 16 years in a row. However, over the past decade, average annual dividend growth for the former has outpaced the latter, with Bristol Myers' dividend increasing by an average of 5.3%, versus 4.4% for Pfizer. Hence, even if Pfizer manages to avoid a dividend cut, in time, the yield gap between these two blue chip dividend stocks will continue to narrow.
Which one comes out on top? Bristol Myers Squibb may beat Pfizer in terms of dividend durability and growth potential, but as the saying goes, past performance is not indicative of future results. Both companies have similar short-term growth forecasts. Analyst forecasts call for Pfizer's sales to fall 1.4% this year, and by 3.8% in 2027, with earnings rising 8.7% this year, but essentially flatlining next year.
As for Bristol Myers Squibb, analyst forecasts call for 2026 and 2027 sales to decline 1.8% and 2.3%, respectively, with earnings rising by 3% this year but declining 2.2% next year. That said, as seen from the anticipated 2026 results, both Pfizer and Bristol Myers may be on track to continue delivering numbers that exceed expectations. Both companies have expanded their pipelines, as well as pursued cost-cutting measures.
Investors continue to take a "wait and see" approach. Since January, Bristol Myers and Pfizer shares have generated total returns of 3.2% and 6.1%, respectively. Both stocks also continue to trade at low valuations, with both stocks trading for just under 9 times forward earnings.
So, which of these healthcare dividend stocks is the better buy?? Both companies are facing similar challenges and uncertainty, but Bristol Myers Squibb scores well on dividend growth and durability; consider it the stronger choice.
Israel "Izzy" Englander may not be a household name, but he's one of America's wealthiest investors, with a net worth of around $26.5 billion. Englander made his fortune as founder and manager of Millennium Management, a multi-strategy hedge fund with over $87 billion in assets under management .
Given its enormous capital base and multi-strategy approach, it's not surprising that the fund's 13F filings with the Securities and Exchange Commission (SEC) list thousands of equity positions. However, among these positions, one stands out as a stock that Englander and his fund appear to be highly bullish on: Bristol Myers Squibb (BMY +0.40%).
Last quarter, Millennium materially increased its position in the company. Although this position accounts for only a tiny portion of its overall portfolio, this "smart money" investor's big buy suggests better times ahead for this pharmaceutical stock, which has been weighed down by upcoming patent expirations for several of its blockbuster drugs.
Image source: Getty Images.
Millennium upped its Bristol Myers Squibb position last quarter According to Millennium's Q1 2026 13F filing, the hedge fund increased its position by 5.8 million shares, from 743,659 to 6,545,442 shares. Even as this position makes up less than a fifth of 1% of the fund's assets under management, last quarter's bullish shift suggests that the fund manager believes the pharma company's shares could make a further recovery.
In fact, during Q1 2026, it appeared as though Bristol Myers Squibb was en route to a recovery. From late 2025 to early 2026, the stock surged by around 25%. A major factor driving this surge may have included a promising quarterly earnings release, which, alongside better-than-expected results, unveiled guidance that also exceeded investor expectations.
Since then, however, Bristol Myers shares have pulled back but remain up by around 1% year to date. The company once again exceeded expectations with its results. Also, Bristol Myers Squibb reiterated its full-year guidance, calling for revenue of $46 billion to $47.5 billion and adjusted earnings per share of $6.05 to $6.35.
However, it's possible that uncertainty surrounding the pending patent expiration for Eliquis, one of the company's top-selling drugs, has led to the recent wave of weakness. So, is Millennium's bullish thesis, as I understand it, breaking? Not necessarily, as the pharmaceutical giant continues its game plan to mitigate the impact of its key near-term headwind.
Today's Change
(
0.40
%) $
0.23
Current Price
$
57.13
Should you follow suit? For the past several years, Bristol Myers Squibb has contended with a major patent cliff, or the expiration of patent exclusivity for not one but several of its top-selling branded drug products. As patents expire, generic drugmakers become free to enter the market. This typically leads to declining sales for the original patented and branded product.
Previously, the company appeared to have recovered from the impact of losing patent exclusivity for its multiple myeloma therapy, Revlimid. Bristol Myers' revenue declined in 2023 but surged to above 2022 levels by 2024, with adjusted earnings recovering in 2025.
This time, however, Bristol Myers Squibb is on the verge of losing exclusivity on several blockbuster drugs, including blood thinner Eliquis and cancer treatment Opdivo. Still, as with the last time the company faced a patent cliff, measures to mitigate the damage could prove effective. For example, creating variations of Opdivo may help to partially extend its patent exclusivity.
The company is also utilizing artificial intelligence (AI) to both reduce costs and to speed up clinical development times for its drug candidate pipeline.
Only time will tell whether these efforts work, but the risk/reward appears favorable. Currently, the stock trades for less than 9 times earnings, and has a 4.6% forward dividend yield to boot. With uncertainty factored so much into its valuation, even a small amount of positive surprises could propel this healthcare stock back to higher price levels.
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $57.27, marking a +1.18% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 2.65%. Elsewhere, the Dow saw a downswing of 1.35%, while the tech-heavy Nasdaq depreciated by 4.18%.
The biopharmaceutical company's shares have seen an increase of 0.62% over the last month, not keeping up with the Medical sector's gain of 3.33% and the S&P 500's gain of 5.47%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.61 per share. This would mark year-over-year growth of 10.27%. At the same time, our most recent consensus estimate is projecting a revenue of $11.67 billion, reflecting a 4.89% fall from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.32 per share and revenue of $47.39 billion, indicating changes of +2.76% and -1.67%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.38% upward. Bristol Myers Squibb is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Bristol Myers Squibb is holding a Forward P/E ratio of 8.95. This represents a discount compared to its industry average Forward P/E of 20.92.
It is also worth noting that BMY currently has a PEG ratio of 0.16. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.51 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions
Campaign highlights unmet needs in myeloma and new science like CELMoD research that is giving patients and their loved ones hope
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the launch of “Investigating Myeloma,” a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the importance of ongoing scientific investigation in multiple myeloma, including an approach called CELMoD research led by BMS, defined as cereblon E3 ligase modulation. CELMoD research focuses on engaging key proteins involved in the disease for breakdown by the cell’s own protein removal system to stimulate the immune system and enhance cancer cell killing. For Mariska, this campaign is deeply personal as she reflects on how research has evolved 20 years after her father, Mickey Hargitay, passed away from the disease.
$BMY announced the launch of the “Investigating Myeloma” campaign in partnership with Mariska Hargitay to spotlight the importance of ongoing research in #MultipleMyeloma, including an investigational approach called CELMoD research.
Share “My father was and remains my hero. Many years have passed since we lost him to multiple myeloma, but I still have questions about the disease that brought down this pillar in my life,” said Mariska. “This campaign is my chance to honor my dad, answer my questions about myeloma, and shine a light on CELMoD research, a remarkable area of scientific inquiry that has emerged since his death and is renewing hope for patients and their loved ones.”
Mickey Hargitay was an actor, champion body builder and family man. Mariska first noticed something might be wrong at her wedding, where Mickey, always so full of life, seemed unusually tired. At the time, she believed he was just overwhelmed with emotion, but looking back now, understands it was a sign that something wasn’t right. True to his spirit, Mickey approached his myeloma diagnosis with a positive attitude and though the treatment landscape looked different than it does today, he fought with everything he had until the end. Her personal journey of reconnecting with Mickey’s story is at the heart of “Investigating Myeloma,” which underscores the critical need for continued scientific investigation.
“Listening to Mariska’s story, I felt an immediate personal connection. I lost my father to multiple myeloma many years ago, and that experience continues to shape how I approach the work we do at BMS,” said Monica Shaw, MD, Senior Vice President, Oncology Commercialization at Bristol Myers Squibb. “I had trained as a physician but was working in industry at the time of his diagnosis, and I remember how difficult it was to truly understand what his options were and how to access them. No patient or family should have to navigate that complexity on their own. That experience fuels my commitment to expanding access, simplifying the journey for patients, and accelerating awareness of new scientific approaches—like CELMoD research—that have the potential to make a meaningful difference for patients living with multiple myeloma.”
Building on more than two decades of pioneering research and development that has transformed the multiple myeloma treatment landscape, BMS continues to drive breakthroughs and advance care across the disease continuum. Guided by an unwavering commitment to patients, BMS is investigating new approaches, including CELMoD research—part of their larger targeted protein degradation platform—to uncover deeper insights into the complex biology of multiple myeloma.
"We are incredibly proud of our long-standing commitment and leadership in advancing the science to better understand multiple myeloma. However, despite significant progress that has transformed this treatable yet still incurable disease, our work is far from over," said Neil Bence, PhD, Senior Vice President, Head of Protein Homeostasis Thematic Research Center at Bristol Myers Squibb. "Our innovative CELMoD research is a cornerstone of our scientific investigation into myeloma. This approach specifically engages cereblon within the cell's natural protein removal system to selectively break down key proteins linked to this disease.”
To learn more about Mariska’s story and to explore multiple myeloma research, visit InvestigatingMyeloma.com.
About Multiple Myeloma
Multiple myeloma is an aggressive blood cancer that begins in the bone marrow, specifically affecting plasma cells, a type of white blood cell. When plasma cells become cancerous, they multiply uncontrollably, leading to various complications including bone damage, kidney problems, weakened immune function, and anemia. With approximately 36,000 new cases diagnosed each year in the U.S., it is the second most common blood cancer. Though advances have improved patient outcomes, multiple myeloma remains incurable and is characterized by a relentless cycle of relapse and progressively shorter remissions, underscoring the critical need for continued research.
About CELMoD Research
Bristol Myers Squibb is dedicated to advancing the understanding and treatment of multiple myeloma. A key area of our scientific investigation is CELMoD (cereblon E3 ligase modulation) research, which is one part of a larger targeted protein degradation platform. This innovative approach explores how to specifically engage cereblon, a protein that plays a crucial role within the body’s natural process for regulating the levels of cellular proteins through their degradation, or breakdown. By focusing our research on modulating cereblon, Bristol Myers Squibb aims to selectively engage proteins that regulate the growth and survival of multiple myeloma cells with potential to stimulate the immune system and enhance killing of cancer cells. This research approach underscores our commitment to pioneering new scientific avenues to expand possibilities for patients facing this complex blood cancer.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
